We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
-4.89%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
-$114M
Cap. Flow
-$31M
Cap. Flow %
-2.92%
Top 10 Hldgs %
68.2%
Holding
44
New
2
Increased
8
Reduced
8
Closed
3

Top Buys

1
HLVX
HilleVax
HLVX
+$110M
2
KRYS icon
Krystal Biotech
KRYS
+$14.3M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$13.9M
4
TARS icon
Tarsus Pharmaceuticals
TARS
+$5.56M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.16M

Top Sells

1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$77.2M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$28.3M
3
BCYC
Bicycle Therapeutics
BCYC
+$26.5M
4
PCVX icon
Vaxcyte
PCVX
+$12.1M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.3M

Sector Composition

1 Healthcare 98.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
26
Autolus Therapeutics
AUTL
$389M
$10.6M 1%
3,746,857
– –
NTLA icon
27
Intellia Therapeutics
NTLA
$1.66B
$10.5M 1%
203,684
– –
SLN
28
Silence Therapeutics
SLN
$516M
$10.4M 0.99%
881,173
– –
TYRA icon
29
Tyra Biosciences
TYRA
$1.88B
$9.83M 0.93%
1,375,065
+47,400
+4% +$377K
STRO icon
30
Sutro Biopharma
STRO
$393M
$9.26M 0.87%
177,648
– –
ACRS icon
31
Aclaris Therapeutics
ACRS
$749M
$5.7M 0.54%
408,329
– –
CERE
32
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$5.35M 0.5%
202,260
+146,425
+262% +$4.16M
TRVI icon
33
Trevi Therapeutics
TRVI
$2.46B
$3.29M 0.31%
+1,171,627
New +$2.88M
PRDS
34
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.6M 0.25%
845,636
-1,235,371
-59% -$7.54M
IMVT icon
35
Immunovant
IMVT
$8B
$2.28M 0.22%
585,759
– –
EPIX
36
DELISTED
ESSA Pharma
EPIX
$2.18M 0.21%
692,910
– –
ISEE
37
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.64M 0.15%
170,000
-2,251,563
-93% -$28.3M
MTEM
38
DELISTED
Molecular Templates, Inc.
MTEM
$1.25M 0.12%
91,603
– –
EPZM
39
DELISTED
Epizyme, Inc
EPZM
$1.09M 0.1%
739,369
– –
APTX
40
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.05M 0.1%
1,883,244
– –
NBRV
41
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$77K 0.01%
17,026
– –
AVDL
42
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-951,814
Closed -$6.5M
BCYC
43
Bicycle Therapeutics
BCYC
$292M
– –
-603,521
Closed -$26.5M
SRRK icon
44
Scholar Rock
SRRK
$6.2B
– –
-156,000
Closed -$2.01M
1
2

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2022 Portfolio in Review

As of Q2 2022, Frazier Life Sciences Management held 44 positions worth $1.06B, down 9.7% from $1.17B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Frazier Life Sciences Management's Q2 2022 filing shows 2 new, 8 increased, 8 reduced and 3 closed positions. Its largest new stake was HilleVax: 9,285,682 shares worth $101M. The largest sale was Sierra Oncology, Inc. Common Stock, an estimated $77.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

  • Frazier Life Sciences Management's largest Q2 2022 buy was HilleVax: 9,285,682 shares worth $101M.
  • Frazier Life Sciences Management added most to Krystal Biotech in Q2 2022, an estimated $14.3M increase.
  • Frazier Life Sciences Management's biggest Q2 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $77.2M.
  • Frazier Life Sciences Management fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $26.5M.
  • Frazier Life Sciences Management's ten largest holdings make up 68% of its $1.06B portfolio in Q2 2022.
  • Frazier Life Sciences Management opened 2 new positions and closed 3 in Q2 2022.
  • Frazier Life Sciences Management's portfolio value fell 9.7% quarter-over-quarter to $1.06B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2022, filed 10 Aug 2022.